127 related articles for article (PubMed ID: 32379370)
1. Bone-Specific Drugs and Osteonecrosis of Sites Other Than the Jaw: A Nationwide Cohort Study.
Nordström P; Bergman J; Ballin M; Björk S; Nordström A
J Bone Miner Res; 2020 Sep; 35(9):1703-1710. PubMed ID: 32379370
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
3. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
5. Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.
Kim SH; Lee YK; Kim TY; Ha YC; Jang S; Kim HY
Bone; 2021 Feb; 143():115650. PubMed ID: 32956854
[TBL] [Abstract][Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
7. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
[TBL] [Abstract][Full Text] [Related]
8. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
[TBL] [Abstract][Full Text] [Related]
9. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Ulmner M; Jarnbring F; Törring O
J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
[TBL] [Abstract][Full Text] [Related]
11. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
12. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
14. Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer.
Goodwin JS; Zhou J; Kuo YF; Baillargeon J
Mayo Clin Proc; 2017 Jan; 92(1):106-113. PubMed ID: 27876314
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
16. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
17. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
18. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
Tennis P; Rothman KJ; Bohn RL; Tan H; Zavras A; Laskarides C; Calingaert B; Anthony MS
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):810-7. PubMed ID: 22711458
[TBL] [Abstract][Full Text] [Related]
19. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.
Etminan M; Aminzadeh K; Matthew IR; Brophy JM
J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]